Cassava Sciences Inc. (NASDAQ:SAVA) stock plunged Monday after the company released topline data from the Phase 3 ReThink-ALZ study of simufilam in mild-to-moderate Alzheimer’s disease. The trial did not meet the pre-specified co-primary, secondary, and exploratory biomarker endpoints. In July, CEO Rick Barry wrote a letter to shareholders and employees, saying that the company is in the final stages of testing simufilam and has significant financial and emotional stakes. The co-primary endpoint
Cassava Sciences Alzheimer’s Drug Fails To Hit Primary Goal In Pivotal Study, Pharma Halts Late-Stage Studies
